Biogem
Composition
Gemcitabine200mg / 1g Vials
Pharmaceutical form
VialsTherapeutic Indications
Pancreatic CancerNon-Small Cell Lung Cancer
Breast Cancer
Bladder Cancer
Ovarian Cancer
Oesophageal Cancer
Posology and method of administration
Single-Agent Use : Pancreatic Cancer Biogem should be administered by intravenous infusion at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment.Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks.
Combination Use
Non-Small Cell Lung Cancer : Two schedules have been investigated and the optimum schedule has not been determined.
With the 4-week schedule, Biogem should be administered intravenously at
1000 mg/m2 over 30 minutes on days 1, 8 and 15 of each 28-day cycle.
Cisplatin should be administered intravenously at 100 mg/m2 on day 1 after the infusion of Biogem.
With the 3-week schedule, Biogem should be administered intravenously at 1250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle.
Cisplatin at a dose of 100 mg/m2 should be administered intravenously after the infusion of Biogem on day 1.
Breast Cancer : Biogem should be administered intravenously at a dose of 1250 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Paclitaxel should be administered at 175 mg/m2 on day 1 as a 3-hour intravenous infusion before Biogem administration.
Ovarian Cancer : Biogem should be administered intravenously at a dose of 1000 mg/m2 over 30 minutes on days 1 and 8 of each 21-day cycle. Carboplatin AUC 4 should be administered intravenously on day 1 after Biogem administration.
Interaction with other pharmaceuticals
Not AvailablePregnancy and lactation
Not AvailableEffects on abilities
Not AvailableOverdose
Not AvailablePharmacological Properties
Not AvailableExcipients
Not AvailableShelf life
Not AvailableStorage
Not AvailablePackaging
1 Vial of 200 mg1 Vial of 1000 mg